Laura Shawver - Jul 3, 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jul 3, 2023
Transactions value $
-$474,703
Form type
4
Date filed
7/6/2023, 08:55 PM
Previous filing
Jun 28, 2023
Next filing
Jul 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $33.7K +26.5K +12.61% $1.27* 237K Jul 3, 2023 Direct
transaction SPRY Common Stock Sale -$178K -26.5K -11.2% $6.73 210K Jul 3, 2023 Direct F1, F2
transaction SPRY Common Stock Options Exercise $39.5K +31.1K +14.79% $1.27* 241K Jul 5, 2023 Direct
transaction SPRY Common Stock Sale -$200K -31.1K -12.89% $6.41 210K Jul 5, 2023 Direct F1, F3
transaction SPRY Common Stock Options Exercise $42.6K +33.5K +15.93% $1.27* 244K Jul 6, 2023 Direct
transaction SPRY Common Stock Sale -$213K -33.5K -13.74% $6.34 210K Jul 6, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -26.5K -13.06% $0.00 176K Jul 3, 2023 Common Stock 26.5K $1.27 Direct F5
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -31.1K -17.63% $0.00 145K Jul 5, 2023 Common Stock 31.1K $1.27 Direct F5
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -33.5K -23.05% $0.00 112K Jul 6, 2023 Common Stock 33.5K $1.27 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.62 to $6.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.21 to $6.75, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.10 to $6.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F5 Immediately exercisable.